NCT06334757 2024-03-28Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureHenan Cancer HospitalPhase 2 Unknown46 enrolled